S&S On Biotech

S&S Ltd.

To continue listening to thought-provoking podcasts on biotech, pharma, and medtech visit: biobizbuzz.com.

Conversations on the science and business of Biotechnology with Andy Smith and Cormac Sheridan.

Escuchar el último episodio:

To continue listening to podcast on biotech, pharma, and medtech visit our new channel: biobizbuzz.com. When the first chimeric antigen receptor T-cell (CAR-T) therapy was approved in 2017, there was a general expectation that T-cell receptor T-cell (TCR-T) therapies would follow shortly afterwards and would greatly expand the range of addressable antigens. Despite considerable efforts, CAR-T therapies are still limited to haematological cancers expressing extracellular antigens, such a...